<h3>领取 55% 折扣 TipRanks</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>发现表现优异的股票想法，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>C4 Therapeutics（(CCCC)）刚刚发布了更新。</p>
<p>C4 Therapeutics, Inc. 宣布，首席会计官 Mark Mossler 将于 2026 年 5 月 15 日离职，公司表示他的离职与财务报告、运营、政策或实践没有任何分歧。自同日起，首席财务官、企业事务负责人和财务主管 Kendra R. Adams 将担任首席会计官的额外职务，现有薪酬或安排不变，表明公司财务领导结构的内部调整以保持连续性。</p>
<p>将会计职责整合到 Adams 之下，表明 C4 Therapeutics 正在精简其高级财务监督，而不增加高管层的成本。对于投资者和其他利益相关者而言，Mossler 离职未报告争议，以及依赖现有高管担任首席会计官的做法，表明公司财务治理在领导层过渡期间的运营稳定性。</p>
<p>最近对 (CCCC) 股票的分析师评级为买入，目标价为 10.00 美元。要查看 C4 Therapeutics 股票的完整分析师预测列表，请访问 CCCC 股票预测页面。</p>
<p><strong>Spark 对 CCCC 股票的看法</strong></p>
<p>根据 Spark，TipRanks 的 AI 分析师，CCCC 的评级为中性。</p>
<p>总体评分主要受到财务表现不佳（持续大额亏损和显著现金消耗）的影响，尽管杠杆水平可控。技术面支持但超买，鉴于负收益，估值较为困难。由于管道进展和与罗氏的合作，企业事件是一个明显的积极因素。</p>
<p>要查看 Spark 对 CCCC 股票的完整报告，请点击这里。</p>
<p><strong>关于 C4 Therapeutics 的更多信息</strong></p>
<p>C4 Therapeutics, Inc. 是一家生物技术公司，专注于开发靶向蛋白降解疗法，运营于生物制药行业。该公司专注于设计小分子药物，利用身体自然的蛋白降解机制来治疗癌症和其他严重疾病，针对专业治疗市场中的未满足医疗需求。</p>
<p><strong>平均交易量：</strong> 3,065,325</p>
<p><strong>技术情绪信号：</strong> 买入</p>
<p><strong>当前市值：</strong> 4.014 亿美元</p>
<p>要全面评估 CCCC 股票，请访问 TipRanks 的股票分析页面。</p>

CCCC

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做多 - Direxion

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

医药突破 ETF - ALPS

<p>C4 Therapeutics 宣布首席会计官 Mark Mossler 将于 2026 年 5 月 15 日离职，且未报告任何分歧。首席财务官 Kendra R. Adams 将担任首席会计官，表明财务领导结构的简化。这一过渡暗示了财务治理的运营稳定性。分析师对 C4 Therapeutics 股票（CCCC）给予 “买入” 评级，目标价为 10.00 美元，尽管对财务表现的担忧仍然存在</p>

<h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>领取 55% 折扣 TipRanks</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>发现表现优异的股票想法，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>C4 Therapeutics ( (CCCC) ) just unveiled an update.</p>
<div class="lb-trans"><p>C4 Therapeutics（(CCCC)）刚刚发布了更新。</p>
</div><p>C4 Therapeutics, Inc. announced that on May 12, 2026, it decided Chief Accounting Officer Mark Mossler will leave his role effective May 15, 2026, with the company stating his departure is not related to any disagreement over financial reporting, operations, policies or practices. Effective the same date, Chief Financial Officer, Head of Corporate Affairs and Treasurer Kendra R. Adams will assume the additional role of principal accounting officer without changes to her existing compensation or arrangements, signaling a continuity-focused, internal realignment of the company’s finance leadership structure.</p>
<div class="lb-trans"><p>C4 Therapeutics, Inc. 宣布，首席会计官 Mark Mossler 将于 2026 年 5 月 15 日离职，公司表示他的离职与财务报告、运营、政策或实践没有任何分歧。自同日起，首席财务官、企业事务负责人和财务主管 Kendra R. Adams 将担任首席会计官的额外职务，现有薪酬或安排不变，表明公司财务领导结构的内部调整以保持连续性。</p>
</div><p>The consolidation of accounting responsibilities under Adams, whose experience and contractual details were previously disclosed in the company’s 2026 proxy filing, suggests C4 Therapeutics is streamlining its senior financial oversight without adding cost at the executive level. For investors and other stakeholders, the absence of reported disputes around Mossler’s departure and the reliance on an existing executive for the principal accounting role point to operational stability in the company’s financial governance despite the leadership transition.</p>
<div class="lb-trans"><p>将会计职责整合到 Adams 之下，表明 C4 Therapeutics 正在精简其高级财务监督，而不增加高管层的成本。对于投资者和其他利益相关者而言，Mossler 离职未报告争议，以及依赖现有高管担任首席会计官的做法，表明公司财务治理在领导层过渡期间的运营稳定性。</p>
</div><p>The most recent analyst rating on (CCCC) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.</p>
<div class="lb-trans"><p>最近对 (CCCC) 股票的分析师评级为买入，目标价为 10.00 美元。要查看 C4 Therapeutics 股票的完整分析师预测列表，请访问 CCCC 股票预测页面。</p>
</div><p><strong>Spark’s Take on CCCC Stock</strong></p>
<div class="lb-trans"><p><strong>Spark 对 CCCC 股票的看法</strong></p>
</div><p>According to Spark, TipRanks’ AI Analyst, CCCC is a Neutral.</p>
<div class="lb-trans"><p>根据 Spark，TipRanks 的 AI 分析师，CCCC 的评级为中性。</p>
</div><p>Overall score is held back primarily by weak financial performance (large ongoing losses and significant cash burn) despite manageable leverage. Technicals are supportive but overbought, and valuation is difficult given negative earnings. Corporate events are a clear positive due to pipeline progress and the Roche collaboration.</p>
<div class="lb-trans"><p>总体评分主要受到财务表现不佳（持续大额亏损和显著现金消耗）的影响，尽管杠杆水平可控。技术面支持但超买，鉴于负收益，估值较为困难。由于管道进展和与罗氏的合作，企业事件是一个明显的积极因素。</p>
</div><p>To see Spark’s full report on CCCC stock, click here.</p>
<div class="lb-trans"><p>要查看 Spark 对 CCCC 股票的完整报告，请点击这里。</p>
</div><p><strong>More about C4 Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 C4 Therapeutics 的更多信息</strong></p>
</div><p>C4 Therapeutics, Inc. is a biotechnology company focused on developing targeted protein degrader therapies, operating in the biopharmaceutical industry. The company concentrates on designing small-molecule medicines that harness the body’s natural protein degradation mechanisms to treat cancer and other serious diseases, targeting unmet medical needs in specialized therapeutic markets.</p>
<div class="lb-trans"><p>C4 Therapeutics, Inc. 是一家生物技术公司，专注于开发靶向蛋白降解疗法，运营于生物制药行业。该公司专注于设计小分子药物，利用身体自然的蛋白降解机制来治疗癌症和其他严重疾病，针对专业治疗市场中的未满足医疗需求。</p>
</div><p><strong>Average Trading Volume:</strong> 3,065,325</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 3,065,325</p>
</div><p><strong>Technical Sentiment Signal:</strong> Buy</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 买入</p>
</div><p><strong>Current Market Cap:</strong> $401.4M</p>
<div class="lb-trans"><p><strong>当前市值：</strong> 4.014 亿美元</p>
</div><p>For a thorough assessment of CCCC stock, go to TipRanks’ Stock Analysis page.</p>
<div class="lb-trans"><p>要全面评估 CCCC 股票，请访问 TipRanks 的股票分析页面。</p>
</div>

C4 Therapeutics 在一位高管离职后重新调整了财务领导层